Department of Cardiac Surgery, Centre Cardiologique du Nord de Saint-Denis, Paris, France.
Department of Clinical and Experimental Medicine, University of Messina, Italy.
Biomed Res Int. 2021 Apr 7;2021:5528006. doi: 10.1155/2021/5528006. eCollection 2021.
We used the radial artery as a second target conduit for coronary artery bypass grafting since 1971. However, randomized clinical studies have demonstrated differences in clinical outcomes between the radial artery and other grafts because these trials are underpowered. As we proceed toward 50 years of experience with radial artery grafting, we examined the literature to define the best second-best target vessel for coronary artery bypass grafting. The literature was reviewed with emphasis, and a large number of randomized controlled trials, propensity-matched observational series, and meta-analyses were identified with a large patient population who received arterial conduit and saphenous vein grafts. The radial artery has been shown to be effective and safe when used as a second target conduit for coronary artery bypass grafting. Results and patency rates were superior to those for saphenous vein grafting. It has also been shown that the radial artery is a safe and effective graft as a third conduit into the territory of the artery right coronary artery. However, there is little evidence based on a few comparable series limiting the use of the gastroepiploic artery. In its fifth decade of use, we can finally deduced that the aorto-to-coronary radial bypass graft is the conduit of choice for coronary operations after the left internal thoracic artery to the left anterior descending artery.
自 1971 年以来,我们一直将桡动脉作为冠状动脉旁路移植术的第二个靶血管。然而,随机临床试验表明桡动脉与其他移植物在临床结果上存在差异,因为这些试验的效力不足。随着我们在桡动脉移植方面的经验接近 50 年,我们查阅了文献,以确定冠状动脉旁路移植术的最佳第二靶血管。重点对文献进行了回顾,并确定了大量的随机对照试验、倾向匹配的观察性系列和荟萃分析,这些研究纳入了接受动脉导管和大隐静脉移植物的大量患者。桡动脉已被证明在用作冠状动脉旁路移植术的第二个靶血管时是有效且安全的。结果和通畅率优于大隐静脉移植。此外,桡动脉作为右冠状动脉区域的第三个导管也被证明是安全有效的。然而,基于少数可比较的系列,几乎没有证据限制使用胃网膜动脉。在使用的第五个十年,我们终于可以推断出,在左内乳动脉至前降支之后,用于冠状动脉手术的首选移植物是主动脉至冠状动脉桡动脉旁路移植。